

Patient Information Leaflet (PIL)

What is Expanded Access Program (EAP)? This Program also known as the Compassionate Use Program, is designed for individuals who do not qualify for clinical trials but have exhausted all available treatment options. The purpose is to provide access to potential therapies that have not yet received regulatory approval.

Introduction about TrueBinding, Inc. TrueBinding is a biotherapeutic company based in California, USA, creating new and exciting molecules for applications in neurodegenerative diseases, stroke, metabolic diseases, oncology, and other areas with great unmet medical need.

What is TB006? TB006 is a recombinant monoclonal antibody against Galectin-3 (Gal-3). Gal-3's involvement in toxic protein oligomer formation, neuroinflammation is highlighting its potential as a therapeutic target. Elevated Gal-3 levels in serum and cerebrospinal fluid are associated with neurodegeneration, cognitive decline, and increased inflammation. By blocking Gal-3, TB006 disrupts the formation of Abeta plaques, reduces microglia activation, enabling neurons to resume communication and potentially reversing the progression of AD.

What are the side effects of using TB006? Up to date, from our phase 1b/2a report, there were no severe adverse events. TB006 was well tolerated and the most common adverse event was infusion reaction. The side effects that have been reported, were mostly mild and lasted only a short time. The most common side effects so far are:

- Headache
- Upset stomach
- Back pain

Please seek treatment immediately and tell your doctor and their staff if you have any of these symptoms.

Who can participate in the Expanded Access Program? For treating Alzheimer's disease or other forms of dementia, the inclusion criteria include male or female patients > 50 years who were diagnosed with symptomatic AD or related dementia, meeting the clinical criteria for AD with an estimated or actual MMSE score of 24 or less. The patient must also



be unable or ineligible to enroll in another clinical trial for their condition, or has tried and failed to the other AD medicines.

What are the costs associated with participating in EAP? Patients are responsible for the treatment and physician-associated fees. Your physician will inform you of the total cost to enroll in EAP.

How does TB006 administered? TB006 treatment is a monthly IV infusion, which takes at least 1 hour. Each dose contains 4000mg of drug. Treatment may continue indefinitely and may be discontinued whenever desired.

What were the results of the clinical trials with TB006? TrueBinding has completed the Phase 1b/2a trial and has completed recruitment for the Open Label Extension (OLE) trial for TB006 combating Alzheimer's disease. The Phase 1b/2a trial reveals promising trends in cognition and function improvement after just one month of treatment. Patients showed improvements in the Clinical Dementia Rating-Sum of Boxes (CDR-SB), indicating a potential slowing or reduction of clinical decline. In the OLE trial nearly half of the patients treated with TB006 for three months or longer showed signs of disease reversal or cognitive improvement.

Topline data can be found here or through our website:

<https://static1.squarespace.com/static/6118e5173909f118e816918e/t/637871ba8ec03853236e7317/1668842422452/TrueBinding-Topline-Release.pdf>

What should I do if I would like to participate in EAP? Contact your doctors first, provide this brochure to them, and have them contact us at EAP@truebinding.com. If you have any questions regarding patient enrollment, you could call us at 650-847-1117. For more information, please visit our website: <https://www.truebinding.com/>.

Thank you for your interest in the Expanded Access Program for TrueBinding's TB006 treatment!